Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumours

Doxorubicin pharmacokinetics were determined in 33 patients with solid tumours who received intravenous doses of 20–320 mg m(−2) HPMA copolymer bound doxorubicin (PK1) in a phase I study. Since assay constraints limited the data at lower doses, conventional analysis was not feasible and a ‘populatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomson, A H, Vasey, P A, Murray, L S, Cassidy, J, Fraier, D, Frigerio, E, Twelves, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374352/
https://www.ncbi.nlm.nih.gov/pubmed/10487619
http://dx.doi.org/10.1038/sj.bjc.6690657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374352/
https://www.ncbi.nlm.nih.gov/pubmed/10487619
http://dx.doi.org/10.1038/sj.bjc.6690657

Ejemplares similares